Belgian biopharma company UCB (UCBJY) announced on Wednesday that its arthritis therapy Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, an inflammatory condition affecting skin and joints.
Citing topline data, UCB (UCBJF) stated that its BE BOLD trial achieved the primary endpoint related to a clinical measure called ACR50, which measures a 50% or greater improvement in American College of Rheumatology response criteria.
Bimzelx indicated superiority compared to Skyrizi in terms of ACR50 with a statistically significant effect over 16 weeks, the company added.
BE BOLD, which enrolled more than 500 adults with active psoriatic arthritis, indicated a well-tolerated safety profile for Bimzelx with no new safety signals, according to UCB (UCBJY).
The parallel group study is the fourth head-to-head study that showed Bimzelx’s superiority in psoriatic disease and the first in PsA.